Loading...
01/11 04:03
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reflects strong financial performance, with a 42% increase in sales and improved margins and losses. However, the lack of a shareholder return plan and vague guidance for 2025 temper the positive sentiment. The Q&A reveals concerns about regulatory and supply chain issues, and management's unclear responses on tariffs and financial goals add uncertainty. Despite the positive revenue growth, the absence of clear guidance and shareholder return plans, along with operational risks, suggest a neutral stock price movement in the short term.
Total Sales $1.577 million (up 42% from $1.114 million in Q1 2024) driven by heightened demand for BIT Solution mobile systems, SIS, and increased revenue from iHP Corporate Services.
Product-Based Revenues $1 million (up 35% from Q1 2024) due to increased sales of BIT Solutions and SIS.
Service Revenues $577,000 (up 56% from Q1 2024) reflecting growth in iHP Corporate Services.
BIT Solutions Sales Approximately $300,000 (up nearly 200% from just over $100,000 in Q1 2024) driven by increased demand.
Technical Support Revenue Increased by 42% indicating more frequent use of equipment by clients.
Gross Margin 60.4% (up from 60.2% in Q1 2024) showing slight improvement in profitability.
Operating Loss Approximately $754,000 (improved from $1.226 million in Q1 2024) indicating better cost management.
Net Loss Approximately $256,000 or $0.01 per share (improved from $1.310 million or $0.07 per share in Q1 2024) reflecting reduced losses.
Cash and Cash Equivalents Approximately $674,000 as of March 31, 2025.
Working Capital $3.8 million as of March 31, 2025.
Shareholder Equity $3.8 million as of March 31, 2025.
Accounts Payable Approximately $700,000 (down from $1.7 million in Q1 2024) indicating improved cash management.
Open Sales Log Increased from $877,000 at the end of 2024 to $1.6 million by the end of Q1 2025, reflecting growth in service offerings and capital equipment purchases.
New Product Launch: TOMI launched the SIS-SA product line, enhancing their innovative offerings.
BIT Solution Sales: BIT Solutions sales reached approximately $300,000, marking nearly a 200% increase from just over $100,000 in Q1 of last year.
Market Expansion: TOMI is expanding its customer outreach through targeted marketing initiatives and strategic partnerships, including collaborations with PBSC and Algafeed.
New Customers: New customers include a division of the U.S. Army, a Children's Hospital in Philadelphia, and additional research universities.
International Distribution: Two international distributors added SteraMist products to their customer base.
New Partnerships: TOMI is working on establishing new partnerships in Panama, Nigeria, Israel, Australia, and Chile.
Sales Growth: Total sales increased by 42% in Q1 2025 compared to Q1 2024, with a 21% increase in April 2025.
Operational Efficiency: Operating loss improved to approximately $754,000 from $1.226 million in the same quarter last year.
Cash Position: As of March 31, 2025, cash and cash equivalents were approximately $674,000.
Strategic Focus: TOMI is focused on enhancing sales infrastructure, establishing new distribution channels, and recruiting qualified business developers.
Future Outlook: TOMI anticipates a positive trend in sales throughout the year for BIT Solution, equipment services, and custom designs.
Competitive Pressures: The company faces challenges in securing bids for Custom Engineered Systems (CES) due to competition, as potential clients may opt for CES over hybrid systems, impacting sales forecasts.
Regulatory Issues: The complexity of the SIS platform and its offerings may involve navigating regulatory requirements, which can delay implementation and affect sales timelines.
Supply Chain Challenges: The manufacturing of enclosures for SIS systems is dependent on external suppliers, which may lead to delays in fulfilling customer orders.
Economic Factors: The ongoing economic environment may impact customer spending and investment in new technologies, potentially affecting sales growth.
Operational Risks: The company is experiencing operational challenges related to the complexity of new product offerings, which may lead to delays in customer onboarding and service delivery.
Sales Growth: In Q1 2025, TOMI achieved a 42% increase in total sales compared to Q1 2024, with a 21% increase in April 2025 compared to April 2024.
BIT Solution Sales: Year-to-date, BIT Solution sales surged by 169% compared to the same period last year, with a nearly 200% increase in Q1 2025.
New Partnerships: TOMI is expanding its customer outreach through targeted marketing initiatives and strategic partnerships, including collaborations with PBSC and Algafeed.
Product Launches: The company launched new service offerings in 2024 and the SIS-SA product line, which is expected to be a game-changer.
Sales Infrastructure: TOMI is enhancing its sales infrastructure by establishing new distribution channels and recruiting qualified business developers.
Revenue Expectations: TOMI anticipates a positive trend in sales throughout 2025, particularly for BIT Solution, equipment services, and custom designs.
Financial Projections: The company expects to maintain a cash position similar to Q1 2025, with a focus on managing working capital.
Open Proposals: The iHP Corporate Service deployment pipeline currently stands at $1 million in open proposals for 2025.
Future Orders: TOMI is negotiating $2 million among five potential orders for Custom Engineered Systems (CES) and expects significant sales from SIS and SIS-SA.
Market Expansion: The company is focused on rebuilding brand presence in Panama, Nigeria, and Israel, and establishing new relationships in Australia and Chile.
Shareholder Return Plan: None
The earnings call reveals a mixed financial performance with a significant revenue decline and a shift from operating income to loss. While there is optimism in strategic partnerships and market expansion, the Q&A section highlights uncertainties, especially regarding FDA approval impacts and international sales efforts. The lack of specific guidance and vague responses to key questions further dampen sentiment. Despite some positive long-term prospects, immediate financial challenges and unclear management responses suggest a negative short-term market reaction.
Despite positive developments like high solution sales margins and potential opportunities in pharma manufacturing, the earnings call reveals significant challenges. A 66% revenue decline, increased operating losses, and regulatory hurdles dampen optimism. The Q&A highlights deferred CapEx projects and vague management responses, adding uncertainty. While there are growth prospects, the lack of concrete timelines and financial guidance tempers expectations. Overall, the mixed signals suggest a neutral stock price movement.
The earnings call reflects strong financial performance, with a 42% increase in sales and improved margins and losses. However, the lack of a shareholder return plan and vague guidance for 2025 temper the positive sentiment. The Q&A reveals concerns about regulatory and supply chain issues, and management's unclear responses on tariffs and financial goals add uncertainty. Despite the positive revenue growth, the absence of clear guidance and shareholder return plans, along with operational risks, suggest a neutral stock price movement in the short term.
The earnings call reveals a 42% revenue increase and reduced operating losses, indicating improved financial performance. Despite management's lack of clear guidance for 2025, strong growth in product and service revenues, along with a significant sales backlog, suggests positive momentum. The Q&A section highlights increased interest in food safety applications and potential regulatory advancements, which could drive demand. While regulatory challenges and unclear guidance are concerns, the overall sentiment is positive due to strong financial results and growth prospects.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
